Postprandial Hyperglycemia in Patients with Type 2 Diabetes Mellitus

[1]  J. Haapakoski,et al.  Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. , 2009, Acta medica Scandinavica. Supplementum.

[2]  L. V. Van Gaal,et al.  Miglitol combined with metformin improves glycaemic control in type 2 diabetes , 2001, Diabetes, obesity & metabolism.

[3]  G. Frost,et al.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. , 2001, American journal of physiology. Endocrinology and metabolism.

[4]  M. Matsuda,et al.  Improved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazone. , 2001, Diabetes care.

[5]  R. Landgraf.  Meglitinide Analogues in the Treatment of Type 2 Diabetes Mellitus , 2000, Drugs & aging.

[6]  S. Aronoff,et al.  Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.

[7]  G. Slama.  Clinical significance of post-prandial blood glucose excursions in type 1 and type 2 diabetes mellitus. , 2000, International journal of clinical practice. Supplement.

[8]  M. Shichiri,et al.  Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. , 2000, Diabetes care.

[9]  D. Owens,et al.  Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes. , 2000, Diabetes care.

[10]  L. Scott,et al.  Miglitol: a review of its therapeutic potential in type 2 diabetes mellitus. , 2000, Drugs.

[11]  A. Karara,et al.  Improved control of mealtime glucose excursions with coadministration of nateglinide and metformin. , 2000, Diabetes care.

[12]  E. Gale,et al.  A randomized, controlled trial comparing insulin lispro with human soluble insulin in patients with Type 1 diabetes on intensified insulin therapy. The UK Trial Group. , 2000, Diabetic medicine : a journal of the British Diabetic Association.

[13]  M. Hanefeld,et al.  Rapid and short-acting mealtime insulin secretion with nateglinide controls both prandial and mean glycemia. , 2000, Diabetes care.

[14]  T. Marbury,et al.  Pharmacokinetics of repaglinide in subjects with renal impairment , 2000, Clinical pharmacology and therapeutics.

[15]  L. Jovanovič,et al.  Metabolic and immunologic effects of insulin lispro in gestational diabetes. , 1999, Diabetes care.

[16]  E. Feskens,et al.  Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.

[17]  P. Roach,et al.  Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Humalog Mix25 Study Group. , 1999, Diabetes care.

[18]  L. Bouter,et al.  Hyperglycaemia is associated with all-cause and cardiovascular mortality in the Hoorn population: the Hoorn Study , 1999, Diabetologia.

[19]  P. Clauson,et al.  A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. , 1999, Diabetes care.

[20]  J. Rybka,et al.  European Comparative Study of 2 Alpha-Glucosidase Inhibitors, Miglitol and Acarbose , 1999 .

[21]  P. Home,et al.  Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers , 1999, European Journal of Clinical Pharmacology.

[22]  R. Landgraf,et al.  A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas , 1999, European Journal of Clinical Pharmacology.

[23]  M. Krempf,et al.  Improvement of blood glucose control in Type 1 diabetic patients treated with lispro and multiple NPH injections , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[24]  M. Hanefeld,et al.  Impaired fasting glucose is not a risk factor for atherosclerosis , 1999, Diabetic medicine : a journal of the British Diabetic Association.

[25]  P. Ebeling,et al.  Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. , 1999, Diabetes care.

[26]  B. Wolffenbuttel,et al.  A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group. , 1999, Diabetes care.

[27]  H. Lebovitz,et al.  Repaglinide versus glyburide: a one-year comparison trial. , 1999, Diabetes research and clinical practice.

[28]  P. Home,et al.  Improved glycemic control with insulin aspart: a multicenter randomized double-blind crossover trial in type 1 diabetic patients. UK Insulin Aspart Study Group. , 1998, Diabetes care.

[29]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[30]  L. Heinemann,et al.  Time-Action Profiles of Novel Premixed Preparations of Insulin Lispro and NPL Insulin , 1998, Diabetes Care.

[31]  W. Malaisse,et al.  Effect of antidiabetic agents on the increase in glycemia and insulinemia caused by refeeding in hereditarily diabetic rats. , 1997, Research communications in molecular pathology and pharmacology.

[32]  L. Vignati,et al.  Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. Multicenter Insulin Lispro Study Group. , 1997, Archives of internal medicine.

[33]  O. Schmitz,et al.  Effects of Amylin and the Amylin Agonist Pramlintide on Glucose Metabolism , 1997, Diabetic medicine : a journal of the British Diabetic Association.

[34]  G. Schernthaner,et al.  The Efficacy and Safety of Miglitol Therapy Compared With Glibenclamide in Patients With NIDDM Inadequately Controlled by Diet Alone , 1997, Diabetes Care.

[35]  J. Mullane,et al.  Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial , 1997, Diabetes.

[36]  N. Fineberg,et al.  Immunologic Effects of Insulin Lispro [Lys (B28), Pro (B29) Human Insulin] in IDDM and NIDDM Patients Previously Treated With Insulin , 1996, Diabetes.

[37]  M. Hanefeld,et al.  Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.

[38]  D. Dills,et al.  Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research Group. , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[39]  R. Rosskamp,et al.  Long-Term Treatment of Type 2 Diabetic Patients with the New Oral Antidiabetic Agent Glimepiride (Amaryl®): A Double-Blind Comparison with Glibenclamide , 1996, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[40]  M. Horowitz,et al.  Hyperglycemia affects cardiovascular autonomic nerve function in normal subjects , 1996, Diabetes Care.

[41]  A. Thomas,et al.  Association of postprandial triglyceride and retinyl palmitate responses with newly diagnosed exercise-induced myocardial ischemia in middle-aged men and women. , 1995, Arteriosclerosis, thrombosis, and vascular biology.

[42]  Y. Yamasaki,et al.  1,5-Anhydro-D-glucitol Evaluates Daily Glycemic Excursions in Well-Controlled NIDDM , 1995, Diabetes Care.

[43]  W. Colburn,et al.  Reduction of Postprandial Hyperglycemia in Subjects With IDDM by Intravenous Infusion of AC137, a Human Amylin Analogue , 1995, Diabetes Care.

[44]  G. Pagano,et al.  Comparison of miglitol and glibenclamide in diet-treated type 2 diabetic patients. , 1995, Diabete & metabolisme.

[45]  D. Peters,et al.  Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus. , 1995, Drugs.

[46]  A. Mengel,et al.  Nerve conduction velocity in man: influence of glucose, somatostatin and electrolytes , 1994, Diabetologia.

[47]  A. Mooradian,et al.  Effect of diabetes, insulin, and glucose load on lipid peroxidation in the rat. , 1994, Metabolism: clinical and experimental.

[48]  T. Salvatore,et al.  Reduction of the acute bioavailability of metformin by the α‐glucosidase inhibitor acarbose in normal man , 1994, European journal of clinical investigation.

[49]  A. Mooradian,et al.  Autoxidative and antioxidative potential of simple carbohydrates. , 1994, Free radical biology & medicine.

[50]  E. Kohner,et al.  Oxygen reactivity in diabetes mellitus: effect of hypertension and hyperglycaemia. , 1994, Clinical science.

[51]  M. Davies,et al.  Loss of the First Phase Insulin Response to Intravenous Glucose in Subjects with Persistent Impaired Glucose Tolerance , 1994, Diabetic medicine : a journal of the British Diabetic Association.

[52]  G. Müller,et al.  Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. I. Binding characteristics. , 1994, Biochimica et biophysica acta.

[53]  G. Müller,et al.  Differential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepiride. , 1994, Biochimica et biophysica acta.

[54]  D. Howey,et al.  [Lys(B28), Pro(B29)]-Human Insulin: A Rapidly Absorbed Analogue of Human Insulin , 1994, Diabetes.

[55]  A. Mooradian,et al.  Effect of simple carbohydrates, casein hydrolysate, and a lipid test meal on ethane exhalation rate. , 1994, Journal of applied physiology.

[56]  B. Hoogwerf,et al.  Effects of the Carbohydrase Inhibitor Miglitol in Sulfonylurea-Treated NIDDM Patients , 1994, Diabetes Care.

[57]  D. McTavish,et al.  Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus. , 1993, Drugs.

[58]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[59]  L. Heinemann,et al.  Action Profile of the Rapid Acting Insulin Analogue: Human Insulin B28Asp , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[60]  N. Hotta,et al.  Long‐term Effect of Acarbose on Glycaemic Control in Non‐insulin‐dependent Diabetes Mellitus: A Placebo‐controlled Double‐blind Study , 1993, Diabetic medicine : a journal of the British Diabetic Association.

[61]  F. Santeusanio,et al.  Therapeutical concentrations of tolbutamide, glibenclamide, gliclazide and gliquidone at different glucose levels: in vitro effects on pancreatic A- and B-cell function. , 1992, Diabetes research and clinical practice.

[62]  R. DeFronzo,et al.  The Metabolic Profile of NIDDM Is Fully Established in Glucose-Tolerant Offspring of Two Mexican-American NIDDM Parents , 1992, Diabetes.

[63]  J. K. Dunn,et al.  Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[64]  B H Frank,et al.  Altering the association properties of insulin by amino acid replacement. , 1992, Protein engineering.

[65]  C. Jackson,et al.  A comparison of the relationships of the glucose tolerance test and the glycated haemoglobin assay with diabetic vascular disease in the community. The Islington Diabetes Survey. , 1992, Diabetes research and clinical practice.

[66]  M. Hanefeld,et al.  Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone , 1991, Diabetes Care.

[67]  J. Lancaster,et al.  Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. , 1991, The New England journal of medicine.

[68]  A. Fontbonne,et al.  Insulin and Cardiovascular Disease: Paris Prospective Study , 1991, Diabetes Care.

[69]  A. Hofman,et al.  Postprandial lipoprotein metabolism in normolipidemic men with and without coronary artery disease. , 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

[70]  A. Nandeuil,et al.  Comparative three-month study of the efficacies of metformin and gliclazide in the treatment of NIDD. , 1991, Diabete & metabolisme.

[71]  E M Kohner,et al.  Retinal blood flow during hyperglycemia. A laser Doppler velocimetry study. , 1990, Investigative ophthalmology & visual science.

[72]  G. Sergi,et al.  Insulin regulation of glucose and lipid metabolism in massive obesity , 1990, Diabetologia.

[73]  L. Groop,et al.  Early metabolic defects in persons at increased risk for non-insulin-dependent diabetes mellitus. , 1989, The New England journal of medicine.

[74]  T. Kondo,et al.  Enteroglucagon release in disaccharide malabsorption induced by intestinal alpha-glucosidase inhibition. , 1989, The American journal of gastroenterology.

[75]  C. Couet,et al.  Metabolic effects of acarbose in young healthy men. , 1989, European journal of clinical nutrition.

[76]  B V Howard,et al.  Impaired glucose tolerance as a disorder of insulin action. Longitudinal and cross-sectional studies in Pima Indians. , 1988, The New England journal of medicine.

[77]  S. Clissold,et al.  Acarbose: A Preliminary Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential , 1988 .

[78]  P. Wilson,et al.  Incidence of Diabetic Retinopathy and Relationship to Baseline Plasma Glucose and Blood Pressure , 1988, Diabetes Care.

[79]  D. Reed,et al.  Postchallenge Glucose Concentration and Coronary Heart Disease in Men of Japanese Ancestry: Honolulu Heart Program , 1987, Diabetes.

[80]  R. Boston,et al.  Lower triglyceride production during carbohydrate-rich diets through acarbose, a glucoside hydrolase inhibitor. , 1985, Diabete & metabolisme.

[81]  H. Keen,et al.  The Bedford Survey: Ten year mortality rates in newly diagnosed diabetics, borderline diabetics and normoglycaemic controls and risk indices for coronary heart disease in borderline diabetics , 1982, Diabetologia.

[82]  K. Alberti,et al.  Scope and Specificity of Acarbose in Slowing Carbohydrate Absorption in Man , 1981, Diabetes.

[83]  P. Bennett,et al.  DEVELOPMENT OF RETINOPATHY AND PROTEINURIA IN RELATION TO PLASMA-GLUCOSE CONCENTRATIONS IN PIMA INDIANS , 1980, The Lancet.

[84]  M. Shipley,et al.  CORONARY-HEART-DISEASE RISK AND IMPAIRED GLUCOSE TOLERANCE The Whitehall Study , 1980, The Lancet.

[85]  H. Keen,et al.  HYPERGLYCÆMIA AND DIABETES MELLITUS , 1976, The Lancet.

[86]  R Luft,et al.  The plasma insulin response to glucose infusion in healthy subjects and in diabetes mellitus. , 1967, Acta endocrinologica.

[87]  D. Giugliano,et al.  Metformin for obese, insulin-treated diabetic patients: improvement in glycaemic control and reduction of metabolic risk factors , 2004, European Journal of Clinical Pharmacology.

[88]  P. Lefèbvre,et al.  Glibenclamide pharmacokinetics in acarbose-treated type 2 diabetics , 2004, European Journal of Clinical Pharmacology.

[89]  B. Wolffenbuttel,et al.  Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM , 2004, European Journal of Clinical Pharmacology.

[90]  S. Colagiuri,et al.  Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. , 1999, Diabetes care.

[91]  C. N. Hales,et al.  Non-insulin-dependent diabetes mellitus. , 1997, British medical bulletin.

[92]  I. Macdonald,et al.  Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM , 1997, Diabetologia.

[93]  G. Pagano,et al.  Metabolic effects of metformin addition to chronic glibenclamide treatment in type 2 diabetes. , 1994, Diabete & metabolisme.

[94]  C. Kilo,et al.  Evaluation of the efficacy and safety of Diamicron in non-insulin-dependent diabetic patients. , 1991, Diabetes research and clinical practice.

[95]  I. Walter‐Sack,et al.  Effects of acarbose on serum lipoproteins in healthy individuals during prolonged administration of a fiber-free formula diet. , 1989, Annals of nutrition & metabolism.